文献速递认知障碍与痴呆

无不可溶沉积时皮质β-淀粉样蛋白与阿尔茨海默病的关联

Association of Cortical β-Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease.
PubMed 文献 · JAMA Neurol · 2019-01-01

该研究基于两个社区队列(ROSMAP和MAP)的尸检数据,在148例无β-淀粉样沉积的老年人中,发现皮质β-淀粉样蛋白与处理速度和视空间能力下降更快相关,且与淀粉样血管病相关,但与情景记忆下降、tau缠结及APOE ε4无关。结论提示可溶性β-淀粉样蛋白可能具有神经毒性,但其神经病理机制可能与典型AD不同。

要点

  • 无β-淀粉样沉积时,皮质β-淀粉样蛋白与处理速度和视空间能力下降更快相关。
  • 该蛋白与淀粉样血管病相关,但与tau缠结密度、情景记忆下降及APOE ε4无关。
  • 结果提示可溶性β-淀粉样蛋白可能是衰老过程中的神经毒性因素。

核心结论

  • 在无β-淀粉样沉积的老年人中,皮质β-淀粉样蛋白与处理速度和视空间能力下降更快相关,支持可溶性β-淀粉样蛋白的神经毒性作用。

研究设计与样本

  • 研究整合了两个社区基于临床-病理的队列研究(Religious Orders Study始于1994年,Rush Memory and Aging Project始于1997年)的数据。
  • 主要分析聚焦于1203例有蛋白质组数据的个体中148例(12.3%)无β-淀粉样沉积者,其死亡时平均(SD)年龄为87.0(7.0)岁,女性84人(56.8%)。

主要发现

  • β-淀粉样蛋白与情景记忆下降无关联,控制淀粉样血管病后认知下降关联不变。
  • APOE ε4和多基因阿尔茨海默风险评分均与β-淀粉样蛋白无关。

临床怎么用

  • 在无β-淀粉样沉积的老年人中,可溶性β-淀粉样蛋白可能提示处理速度和视空间能力下降风险。
  • 淀粉样血管病可能部分介导该认知下降,但控制后关联仍存在,提示其他机制。
  • APOE ε4阴性且无沉积的个体仍可能因可溶性β-淀粉样蛋白出现认知下降,需进一步研究。

局限性

  • 主要分析样本量较小(148例无β-淀粉样沉积者)。
  • 研究为观察性队列,不能确定因果关系。
  • β-淀粉样蛋白测量采用靶向蛋白质组学,可能未涵盖所有异构体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: β-Amyloid deposits are a pathologic hallmark of Alzheimer disease (AD). However, the extent to which cortical β-amyloid protein in the absence of insoluble deposits is associated with classic features of AD appear to be unknown. OBJECTIVE: To examine the associations of cortical β-amyloid protein in the absence of insoluble deposits with cognitive decline, neurofibrillary tangles, other age-associated neuropathologic conditions, and APOE. DESIGN, SETTING, AND PARTICIPANTS: This analysis combines data from 2 community-based clinicopathologic cohort studies of aging. The Religious Orders Study started in 1994, and the Rush Memory and Aging Project started in 1997. Both studies are ongoing. Participants without known dementia were enrolled and agreed to annual clinical evaluations and brain donation after death. Primary analyses focused on individuals without β-amyloid deposits. Data analyses occurred in mid-September 2018. MAIN OUTCOMES AND MEASURES: β-Amyloid protein abundance was measured by targeted proteomics using selected reaction monitoring. β-Amyloid deposits were detected using immunohistochemistry. Other neuropathologic indices were quantified via uniform structured evaluation. Linear mixed models were used to examine the association of β-amyloid protein with cognitive decline. Regression models examined the protein associations with neuropathologic outcomes and the APOE genotype. RESULTS: By mid-September 2018, 3575 older persons were enrolled, and 1559 had died and undergone brain autopsy. Proteomic data were collected in 1208 individuals, and 5 with missing cognitive scores were excluded. Of the remaining 1203, primary analyses focused on 148 individuals (12.3%) without β-amyloid deposits. In this group, the mean (SD) age at death was 87.0 (7.0) years, and 84 individuals (56.8%) were women. In the absence of β-amyloid deposits, we did not observe an association of β-amyloid protein with decline in episodic memory, but the protein was associated with faster rates of decline in processing speed (mean [SE] change, -0.014 [0.005]; P = .008) and visuospatial abilities (mean [SE] change, -0.013 [0.005]; P = .006). We did not observe protein association with paired helical filament tau tangle density. The protein was associated with amyloid angiopathy (odds ratio, 1.38 [95% CI, 1.15-1.67]; P < .001) but no other brain pathology. The associations with cognitive decline were unchanged after controlling for amyloid angiopathy. Neither APOE ε4 nor a polygenic Alzheimer risk score was associated with β-amyloid protein. CONCLUSIONS AND RELEVANCE: Cortical β-amyloid protein was associated with faster cognitive decline in the absence of β-amyloid deposits, which supports the role of cortical soluble β-amyloid as a neurotoxic agent in aging. The lack of protein association with paired helical filament tau tangles, episodic memory decline, or strong genetic drivers of deposited β-amyloid suggests an underlying neuropathologic change that may differ from that of AD.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Yu L, Petyuk VA, Tasaki S, et al. Association of Cortical β-Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease. JAMA Neurol. 2019. PMID: 31009033. doi:10.1001/jamaneurol.2019.0834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。